...
首页> 外文期刊>Pediatrics: Official Publication of the American Academy of Pediatrics >One Dose of Varicella Vaccine Does Not Prevent School Outbreaks: Is it Time for a Second Dose?
【24h】

One Dose of Varicella Vaccine Does Not Prevent School Outbreaks: Is it Time for a Second Dose?

机译:一剂水痘疫苗不能预防学校暴发:是第二剂时间了吗?

获取原文

摘要

OBJECTIVES. The implementation of a routine childhood varicella vaccination program in the United States in 1995 has resulted in a dramatic decline in varicella morbidity and mortality. Although disease incidence has decreased, outbreaks of varicella continue to be reported, increasingly in highly vaccinated populations. In 2000, a varicella vaccination requirement was introduced for kindergarten entry in Arkansas. In October 2003, large numbers of varicella cases were reported in a school with high vaccination coverage. We investigated this outbreak to examine transmission patterns of varicella in this highly vaccinated population, to estimate the effectiveness of 1 dose of varicella vaccine, to identify risk factors for vaccine failure, and to implement outbreak control measures.METHODS. A retrospective cohort study involving students attending an elementary school was conducted. A questionnaire was distributed to parents of all of the students in the school to collect varicella disease and vaccination history; parents of varicella case patients were interviewed by telephone. A case of varicella was defined as an acute, generalized, maculopapulovesicular rash without other apparent cause in a student or staff member in the school from September 1 to November 20, 2003. Varicella among vaccinated persons was defined as varicella-like rash that developed 42 days after vaccination. In vaccinated persons, the rash may be atypical, maculopapular with few or no vesicles. Cases were laboratory confirmed by polymerase chain reaction, and genotyping was performed to identify the strain associated with the outbreak.RESULTS. Of the 545 students who attended the school, 88% returned the questionnaire. Overall varicella vaccination coverage was 96%. Forty-nine varicella cases were identified; 43 were vaccinated. Three of 6 specimens tested were positive by polymerase chain reaction. The median age at vaccination of vaccinated students in the school was 18 months, and the median time since vaccination was 59 months. Forty-four cases occurred in the East Wing, where 275 students in grades kindergarten through 2 were located, and vaccination coverage was 99%. In this wing, varicella attack rates among unvaccinated and vaccinated students were 100% and 18%, respectively. Vaccine effectiveness against varicella of any severity was 82% and 97% for moderate/severe varicella. Vaccinated cases were significantly milder compared with unvaccinated cases. Among the case patients in the East Wing, the median age at vaccination was 18.5 and 14 months among non–case patients. Four cases in the West Wing did not result in further transmission in that wing. The Arkansas strains were the same as the common varicella-zoster virus strain circulating in the United States (European varicella-zoster virus strain).CONCLUSIONS. Although disease was mostly mild, the outbreak lasted for ~2 months, suggesting that varicella in vaccinated persons was contagious and that 99% varicella vaccination coverage was not sufficient to prevent the outbreak. This investigation highlights several challenges related to the prevention and control of varicella outbreaks with the 1-dose varicella vaccination program and the need for further prevention of varicella through improved vaccine-induced immunity with a routine 2-dose vaccination program. The challenges include: 1-dose varicella vaccination not providing sufficient herd immunity levels to prevent outbreaks in school settings where exposure can be intense, the effective transmission of varicella among vaccinated children, and the difficulty in the diagnosis of mild cases in vaccinated persons and early recognition of outbreaks for implementing control measures. The efficacy of 2 doses of varicella vaccine compared with 1 dose was assessed in a trial conducted among healthy children who were followed for 10 years. The efficacy for 2 doses was significantly higher than for 1 dose of varicella vaccine. This higher efficacy translated into a 3.3-fold lower risk of developing varicella 42 days after vaccination in 2- vs 1-dose recipients. Of the children receiving 2 doses, 99% achieved a glycoprotein-based enzyme-linked immunosorbent assay level of ≥5 units (considered a correlate of protection) 6 weeks after vaccination compared with 86% of children who received 1 dose. The 6-week glycoprotein-based enzyme-linked immunosorbent assay level of ≥5 units has been shown to be a good surrogate for protection from natural disease. Ten years after the implementation of the varicella vaccination program, disease incidence has declined dramatically, and vaccination coverage has increased greatly. However, varicella outbreaks continue to occur among vaccinated persons. Although varicella disease among vaccinated persons is mild, they are contagious and able to sustain transmission. As a step toward better control of varicella outbreaks and to reduce the impact on schools and public health officials, in June 200
机译:目标1995年美国实施了常规的儿童水痘疫苗接种计划,导致水痘发病率和死亡率急剧下降。尽管疾病的发病率下降了,但仍继续报告水痘的暴发,在高度接种疫苗的人群中水痘的爆发越来越多。 2000年,对阿肯色州的幼儿园入学实行了水痘疫苗接种要求。 2003年10月,一所疫苗接种率很高的学校报告了大量水痘病例。我们调查了这次疫情,以检查在高度接种疫苗的人群中水痘的传播方式,评估1剂水痘疫苗的有效性,确定疫苗失败的风险因素以及实施爆发控制措施。进行了一项回顾性队列研究,涉及就读小学的学生。向学校所有学生的父母分发了一份问卷,以收集水痘病和疫苗接种史;通过电话采访了水痘病例患者的父母。一例水痘病例是指2003年9月1日至11月20日在校学生或工作人员在没有其他明显原因的情况下出现的急性,全身性,多发性青光眼球状皮疹。在接种疫苗的人中,水痘被定义为发展为>接种后42天。在接种疫苗的人中,皮疹可能是不典型的,黄斑丘疹,囊泡很少或没有囊泡。通过聚合酶链反应在实验室确认病例,并进行基因分型以鉴定与暴发有关的菌株。在545名就读学校的学生中,有88%返回了调查表。水痘疫苗接种的总覆盖率为96%。鉴定出49例水痘病例;接种了43疫苗。通过聚合酶链反应,测试的6个样本中有3个呈阳性。学校中接种疫苗的学生的平均接种年龄为18个月,自接种疫苗以来的平均时间为59个月。东翼地区发生了44起病例,其中有275名幼儿园至2年级的学生,疫苗接种率达99%。在这支队伍中,未接种疫苗的学生和接种疫苗的学生的水痘发作率分别为100%和18%。针对任何严重程度的水痘的疫苗有效率为82%,中度/重度水痘的疫苗有效性为97%。与未接种疫苗的病例相比,接种疫苗的病例明显较轻。在东翼的病例患者中,非病例患者的疫苗接种中位年龄为18.5岁和14个月。西翼的四起案件并未导致该翼进一步传播。结论阿肯色州毒株与美国流行的水痘带状疱疹病毒株相同(欧洲水痘带状疱疹病毒株)。尽管该病多数为轻度疾病,但爆发持续了约2个月,这表明接种疫苗的人中的水痘具有传染性,并且99%的水痘疫苗接种率不足以预防该病的爆发。这项调查突出了与用1剂量水痘疫苗接种计划预防和控制水痘暴发有关的若干挑战,以及通过常规2剂量疫苗接种计划通过提高疫苗诱导的免疫力进一步预防水痘的挑战。面临的挑战包括:1剂量的水痘疫苗接种不能提供足够的牛群免疫水平,以防止在可能会大量暴露的学校环境中暴发,水痘在疫苗接种儿童中的有效传播以及在疫苗接种者和早期诊断轻度病例的难度认识到实施控制措施的爆发。在接受随访10年的健康儿童中进行的一项试验中,评估了2剂水痘疫苗与1剂疫苗的疗效。 2剂疫苗的功效显着高于1剂水痘疫苗的功效。这种较高的功效使接种2或1剂量的受试者接种水痘> 42天后> 42天的风险降低了3.3倍。接种疫苗后6周,接受2剂疫苗的儿童中,有99%达到了基于糖蛋白的酶联免疫吸附测定≥5个单位(考虑到保护作用),而接受1剂疫苗的儿童中有86%。六周基于糖蛋白的酶联免疫吸附测定水平≥5个单位已被证明是预防自然疾病的良好替代方法。水痘疫苗接种计划实施十年后,疾病发病率急剧下降,疫苗接种范围大大增加。但是,在接种疫苗的人群中水痘暴发继续发生。尽管接种疫苗的人中的水痘病很轻,但它们具有传染性并且能够维持传播。为了更好地控制水痘疫情并减少对学校和公共卫生官员的影响,200年6月
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号